Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.

摘要: Abstract K-RAS gene mutations have been found in 20–30% of non-small cell lung cancer and occur most commonly adenocarcinoma, however, there was no definitive conclusion about the prognostic role NSCLC. Herein we performed a systematic review literatures with meta-analysis to assess mutations’ value After methodological assessment, survival data from published studies were aggregated. Combined hazard ratios (HRs) corresponding 95% confidence intervals (CIs) calculated terms overall survival. 41 trials (6939 patients) included analysis, HR 1.45 (95% CI: 1.29–1.62), showing that an unfavorable impact on patients Then subgroup analysis ethnicity, combined 1.97 1.58–2.44) for Asians, 1.37 1.25–1.5) non-Asians. In histology, 1.39 1.24–1.55) suggesting correlated shortened adenocarcinoma. When conducted according disease stage, poor factors early stages: stage I (1.81; 1.36–2.39) I–IIIa (1.68; 1.11–2.55), but not advanced (IIIb–IV) (1.3; 0.99–1.71). At last, test methods, all four methods: PCR–MSOP (1.73; 1.35–2.2), PCR–DGGE (1.27; 1.01–1.62), PCR–RFLP (1.88; 1.42–2.49) PCR–seq (1.34; 1.14–1.58) showed statistically significant NSCLC patients. conclusion, this suggests are associated worse NSCLC, especially adenocarcinoma stage.